Join our smart investors - Get the best stock directories in  blockchain, cannabis, crypto, AI, IoT, cleantech. Daily podcasts in cannabis and crpto. Just $99  a year

Cell Therapy Market to Grow Beyond Oncology As Big Pharma Expands Investments

Collaborative business approach and adoption of value-based pricing models will create growth opportunities, finds Frost & Sullivan

 

Santa Clara, Calif. - January 17, 2019 (Investorideas.com Newswire) Focus on precision medicine is encouraging R&D across the cell therapy market with Big Pharma/Bio-Pharma responding through collaborations with small to mid-segment players with niche therapeutic focus, thereby gaining a competitive edge with respect to therapy, technology as well as geographic spread. The market was valued at $2.70 billion in 2017 and is expected to reach $8.21 billion in 2025, growing at a robust compounded annual growth rate (CAGR) of 14.9% between 2017 and 2025. A diverse therapeutic focus, accompanied by rising M&A activities and implementation of advanced manufacturing technologies such as single-use bioreactors, will pave a way for unique cell-gene and stem cell – gene combination therapies.

"In addition to collaborations, pharmas are employing a pay-for-performance business model that allows the payer to pay based on the therapeutic outcome of the high-value therapy,” said Aarti Chitale Senior Research Analyst Transformational Health. "Novartis and Gilead are among the first companies to adopt this pricing model for their ground-breaking CAR-T Cell therapies Kymriah® and Yescarta®, respectively. In addition to innovative pricing models, Pharma companies are also showing a preference for risk sharing and fast-to-market models in order to support the development of novel therapies."

Frost & Sullivan's recent analysis, Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025, presents revenue analysis at global and regional levels, as well as some of the key market drivers and restraints that affect long-term growth. There is also a focus on the regulatory challenges to market expansion and drug development across emerging markets, including China and South Korea.

For further information on this analysis, please visit: http://frost.ly/31s.

"Amendments in regulatory and reimbursement policies, as well as the implementation of conditional approval policies for RM, will further drive the market by expediting product launches," noted Chitale. "Additionally, improvements in cell culturing techniques alongside the use of different stem cells such as adipose-derived stem cells (ADSCs), mesenchymal stem cells (MSCs), and induced Pluripotent Stem Cell will strengthen the market with superior treatment options for non-oncological conditions such as neurological, musculoskeletal, and dermatological conditions."

With the rising demand for cell therapies, the following growth opportunities have multiplied for vendors:

  • Wide-ranging therapeutic focus across both oncology and non-oncology conditions. With more than 959 ongoing regenerative medicine clinical trials, the market finds opportunity across both stem cell and non-stem cell based therapies.
  • Curative Combination Therapies which help to improve response rates among patients while reducing the duration of response. These therapies also find application in identifying the right patient as well as predicting the immune response in cancer patients.
  • Manufacturing Automation by means of implementation of IT solutions and single-use manufacturing techniques for optimizing small-volume, high-value manufacturing of novel cell therapies, thereby reducing the time to market drastically.
  • Emerging Business Models which help market players focus on academic and research collaborations alongside industry collaborations to support therapeutic and technological innovations.

Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025 is part of Frost & Sullivan's global Life Sciences Growth Partnership Service program.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025

PA1F-52

Contact:

Mariana Fernandez
Corporate Communications
T: +1 210 348 10 12
E: Mariana.Fernandez@frost.com

http://ww2.frost.com


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks


More Info:

Investorideas.com Newswire

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp